ライフサイエンスコーパス: febrile

1 At triage, 30.7% of patients were febrile, 17.3% had a respiratory rate greater than 24 br

2 irect effectiveness (surveillance study) was febrile acute respiratory illness in an unvaccinated hou

3 nfirmed influenza in a vaccinated child with febrile acute respiratory illness, analysed in the modif

4 ways at clinical presentation would identify febrile adults at risk of death.

5 Of 507 febrile adults, 32 died (6.3%) within 28 days of present

6 agement of shock, but increased mortality in febrile African children in the FEAST trial.

7 n those with DHF or dengue fever (DF) during febrile and critical phases.

8 disability with delayed speech, a history of febrile and/or non-febrile seizures, and a wide-based, s

9 At presentation he was febrile at 40.1 degrees C but hemodynamically stable.

10 including aphthae, gastrointestinal disease, febrile attacks, and small-vessel vasculitis characteris

11 septic shock, 207 of 378 (55%; 50-60%) were febrile by history or measurement.

12 Of all febrile cases in the study, DENV-positive C cases accoun

13 nalyze changes by month to the proportion of febrile cases prescribed a blood culture compared with t

14 y passive case detection, with management of febrile cases.

15 from blood and 132 from fecal samples) from febrile children <5 years of age were studied.

16 investigated autoantibody (AAb) profiles in febrile children (<= 5 years) admitted to a hospital in

17 l 2018, data were prospectively collected on febrile children aged 0-18 years presenting to 12 EDs in

18 otic and broad-spectrum prescriptions in all febrile children are lacking.

19 ) to decide on antibiotic prescription among febrile children at risk of pneumonia has not been teste

20 e included EDs are not representative of all febrile children attending EDs in that country.

21 cterize dengue virus (DENV) infections among febrile children enrolled in a pediatric cohort study wh

22 was conducted to estimate the proportion of febrile children hospitalized at the study hospitals.

23 Clinical management of febrile children in these settings is difficult given th

24 the e-POCT tool was non-inferior to that of febrile children managed by a validated electronic algor

25 to determine whether the clinical outcome of febrile children managed by the e-POCT tool was non-infe

26 From 2008 to 2016, febrile children or children with a history of fever age

27 ppropriateness of antibiotic prescription in febrile children visiting EDs in Europe.

28 prescription rate of antibiotics is high for febrile children visiting the emergency department (ED),

29 arried out with plasma samples obtained from febrile children with confirmed bacterial infection (n =

30 In the resuscitation of febrile children, albumin and saline boluses can cause r

31 In all febrile children, antibiotic prescriptions were appropri

32 inguishing bacterial from viral infection in febrile children, to facilitate effective clinical manag

33 ntibiotics and broad-spectrum antibiotics in febrile children.

34 KD and matched febrile control sera did not demonstrate differences in

35 mperature, blood pressure, and heart rate in febrile critically ill patients.

36 s arthropod-borne viral pathogens that cause febrile disease in humans.

37 ratyphi A, is the leading cause of bacterial febrile disease in South Asia.

38 (CHIKV), a mosquito-borne alphavirus, causes febrile disease, muscle and joint pain, which can become

39 an emerging vector-borne pathogen causing a febrile disease.

40 oding human nucleoporin NUP214 causing acute febrile encephalopathy.

41 The primary outcome was time to first febrile episode or death from all causes within the firs

42 st 12 weeks of therapy significantly reduced febrile episodes and deaths compared with placebo withou

43 ity and age, altering the risk of developing febrile episodes and suggesting that host immunity plays

44 95 (19%) first febrile episodes or deaths occurred in 489 patients in t

45 levated temperature conditions that simulate febrile episodes, especially at the beginning of the par

46 rations of HRP2 were substantially higher in febrile HRP2-positive patients than in afebrile HRP2-pos

47 In addition, a new febrile hyperinflammatory Kawasaki-like syndrome (also k

48 y hospitalizations with acute respiratory or febrile illness (ARFI) and clinician-ordered real-time r

49 lizations for acute respiratory infection or febrile illness (ARFI) and influenza-associated ARFI amo

50 ies: healthy control, nonfebrile DENV, other febrile illness (OFI), and apparent DENV using multivari

51 T) are widely used to treat undifferentiated febrile illness (UFI).

52 tober 2017 met study criteria for confirmed (febrile illness and culture positivity or >=four-fold ri

53 V) is a mosquito-borne RNA virus that causes febrile illness and debilitating arthralgia in humans.

54 ungo virus infection presented with an acute febrile illness and died rapidly from massive hemorrhage

55 determinants of healthcare seeking for acute febrile illness and enteric fever risk in these communit

56 d by neurologic regression in the setting of febrile illness and other stressors.

57 riates were explored as risk factors for RSV febrile illness and RSV pneumonia or hospitalization.

58 help improve interpretation of the burden of febrile illness and shape policy on fever case managemen

59 >=four-fold rise in SAT titre) or probable (febrile illness and single SAT titre >=160) brucellosis.

60 Kawasaki disease is an acute febrile illness and systemic vasculitis of unknown aetio

61 Pacific Coast tick fever is a febrile illness associated with the bite of Dermacentor

62 ikely to be taken to the study hospitals for febrile illness at all sites.

63 Dengue is an acute febrile illness caused by dengue virus (DENV) and a majo

64 havirus that causes explosive epidemics of a febrile illness characterized by debilitating arthralgia

65 dardised surveillance of blood culture-based febrile illness in 13 African sentinel sites with previo

66 an genotype ZIKAV caused an outbreak of mild febrile illness in 2007 in Yap State, Federated States o

67 aria-endemic settings, accurate diagnosis of febrile illness in children is challenging.

68 s (CCHFV) is a tick-borne pathogen causing a febrile illness in humans, which can progress to hemorrh

69 of 250,1.2%), the agent of eschar-associated febrile illness in humans.

70 esistant infection among patients with acute febrile illness in India.

71 ion, we estimate incidence of RSV-associated febrile illness in the first 6 months of life and identi

72 sease are major causes of invasive bacterial febrile illness in the sampled locations, most commonly

73 7 plasma samples collected 2-12 months after febrile illness in Western and coastal Kenya (1993-2016)

74 ciated with infectious mononucleosis (IM), a febrile illness in which patients have high circulating

75 rizing healthcare-seeking patterns for acute febrile illness is critical for generating population-ba

76 it neurological regression in the setting of febrile illness or infection.

77 management of children with undifferentiated febrile illness outside of malaria are not well understo

78 tissues and initially causes a self-limiting febrile illness similar to dengue.

79 Mayaro virus (MAYV) causes an acute febrile illness similar to that produced by chikungunya

80 kungunya fever (CHIKF), a self-limited acute febrile illness that can progress to chronic arthralgic

81 ever is often self-limiting, presenting as a febrile illness that can result in atypical pneumonia.

82 hi A, frequently presents as a nonlocalizing febrile illness that is difficult to distinguish from ot

83 causes human monocytic ehrlichiosis (HME): a febrile illness that may progress to fatal sepsis with m

84 For most children, malaria is a febrile illness that resolves with time, but in ~1% of c

85 k, and surgical sites who had a diagnosis of febrile illness that was either suspected or blood cultu

86 ldren aged 2-59 months presenting with acute febrile illness to 9 outpatient clinics in Dar es Salaam

87 ic illness ranges from a mild, self-limiting febrile illness to one manifested by plasma leakage that

88 the PERFORM (Personalised Risk assessment in Febrile illness to Optimise Real-life Management across

89 Human disease ranges from mild febrile illness to severe fatal neurologic infection.

90 -Congo haemorrhagic fever (CCHF) is a severe febrile illness transmitted by Hyalomma ticks in endemic

91 Plasmodium falciparum infections lead to febrile illness unless the host has sufficient immunity,

92 History of tick bites and tick-related febrile illness were assessed as part of a case-control

93 Subsequent peaks of febrile illness were found to incorporate smaller outbre

94 Participants presenting with febrile illness were tested for virologically confirmed

95 Participants presenting with febrile illness were tested for virologically confirmed

96 ease following VEEV infection manifests as a febrile illness with flu-like symptoms, which can progre

97 kungunya virus (CHIKV) infection is an acute febrile illness with polyarthralgia and arthritis.

98 Among 1524 patients hospitalized with acute febrile illness, 133 isolates were found among 115 patie

99 ptomatic dengue patients experience an acute febrile illness, 5-20% progress to severe infection asso

100 We evaluated spatial heterogeneity in febrile illness, care seeking, and enteric fever inciden

101 a blood culture compared with the burden of febrile illness, stratified by hospital.

102 Infection with WNV results in febrile illness, which can progress to severe neurologic

103 supportive treatment to dengue patients with febrile illness, which is difficult to diagnose clinical

104 15, for occurrence of acute undifferentiated febrile illness, with clinical and laboratory data avail

105 and Southeast Asia and a rare cause of acute febrile illness, Zika virus (ZIKAV) arose from obscurity

106 nfants and children who suffered episodes of febrile illness-induced neurodegeneration or cardiac fai

107 and cephalosporins) typically used for acute febrile illness.

108 upils, and diffuse anhidrosis 7 days after a febrile illness.

109 c use in primary care patients with an acute febrile illness.

110 ons about healthcare seeking in the event of febrile illness.

111 an arthropod-borne emerging pathogen causing febrile illness.

112 in one) neurological deterioration during a febrile illness.

113 Arboviral infections are frequent causes of febrile illness.

114 diomyopathy with lactic acidosis following a febrile illness.

115 VFV infection mainly include a self-limiting febrile illness.

116 othelial parameters between dengue and other febrile illness.

117 of the genus Flavivirus and can cause severe febrile illness.

118 to potential coinfection with a non-malarial febrile illness.

119 known to circulate for decades causing mild febrile illness.

120 chment area to characterize care seeking for febrile illness.

121 responsible for sporadic outbreaks of acute febrile illness.

122 0.85; 95% CI, 0.81 to 0.90), and nonmalarial febrile illnesses (1122 vs. 1424 episodes; incidence rat

123 matology can be easily confounded with other febrile illnesses (e.g., dengue fever and leptospirosis)

124 sts (RDTs) for common acute undifferentiated febrile illnesses are often used inappropriately.

125 milar adjustments may be indicated for other febrile illnesses for which QT-interval-prolonging medic

126 Using prevalence data of 5 common febrile illnesses from India and Cambodia, and performan

127 ial to transform clinical diagnosis of acute febrile illnesses in resource-limited settings.

128 reatment of patients with non-specific acute febrile illnesses is not considered.

129 Acute febrile illnesses such as dengue and chikungunya, which

130 mprove the clinical outcome of children with febrile illnesses while reducing antibiotic use through

131 for the diagnosis of acute undifferentiated febrile illnesses with presently available tests, which

132 e the disease into differential diagnosis of febrile illnesses with unknown etiology.

133 suspected enteric fever, controls with other febrile illnesses, and healthy controls in Dhaka, Bangla

134 gue and other pathogens that can cause acute febrile illnesses, the search for secondary pathogens wi

135 be infected with other co-circulating acute febrile illnesses.

136 TREM-1 at clinical presentation can identify febrile individuals at risk of all-cause febrile mortali

137 the course of medical care of 0- to 3-mo-old febrile infants (n = 913) and subsequently archived at -

138 mmonly used or optimal thresholds identified febrile infants 60 days or younger with IBIs with high a

139 Clinicians often risk stratify young febrile infants for invasive bacterial infections (IBIs)

140 in reaction-based testing for SARS-CoV-2 for febrile infants in an outbreak setting.

141 eported successful treatment of a child with febrile infection-related epilepsy syndrome (FIRES), a s

142 Dengue fever is an acute febrile infectious disease caused by dengue virus (DENV)

143 Immunisation reduced maternal febrile influenza-like illness with an overall efficacy

144 l presentation and management of a cohort of febrile Kenyan children at five hospital/clinic sites fr

145 Virus-associated febrile lower respiratory tract infections (fLRIs) durin

146 cMSP33D7 had a significantly reduced risk of febrile malaria (adjusted hazard ratio, 0.36 [95% confid

147 mia was associated with an increased risk of febrile malaria in children of all ages.

148 itemia was associated with a reduced risk of febrile malaria in older children (> 3 years), while in

149 ally distinct from those of individuals with febrile malaria in the transmission season, coinciding w

150 es previously shown to be protective against febrile malaria in this same cohort were significantly a

151 her probability of children not experiencing febrile malaria.

152 itemia in determining the risk of developing febrile malaria.

153 itemia in determining the risk of developing febrile malaria.

154 ver 11325 child-years of follow-up to detect febrile malaria.

155 thout conferring enhanced protection against febrile malaria.

156 .30-.73; P = .0008) with protection against febrile malaria.

157 ntigens were associated with protection from febrile malaria.

158 production in some individuals during acute febrile malaria.

159 ify febrile individuals at risk of all-cause febrile mortality.

160 25 [51%]), anaemia (25 [47%] and 24 [49%]), febrile neutropaenia (17 [32%] and 21 [43%]), and pneumo

161 a (51%), infections (24%), anemia (12%), and febrile neutropenia (10%).

162 There were 29 episodes of febrile neutropenia (10%).

163 , were neutropenia (340 [15%] vs 328 [15%]), febrile neutropenia (112 [5%] vs 142 [6%]), and leucopen

164 rade 3 or worse were neutropenia (20 [30%]), febrile neutropenia (12 [18%]), and thrombocytopenia (si

165 sed neutrophil count (31 [12%] vs 27 [11%]), febrile neutropenia (14 [6%] vs 16 [6%]), diarrhoea (12

166 re than 28 days (32%), infections (20%), and febrile neutropenia (14%).

167 of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, a

168 thrombocytopenia (30%), hypertension (15%), febrile neutropenia (15%), and lung infection (11%).

169 common grade 3 or 4 adverse events included febrile neutropenia (16 [41%] of 39), neutropenia (12 [3

170 8 [3%]), bone pain (16 [5%] vs 5 [2%]), and febrile neutropenia (16 [5%] vs 9 [3%]).

171 reatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic

172 he most common grade 3-4 adverse events were febrile neutropenia (22 [66%]), bloodstream infections (

173 gher with ramucirumab than with placebo were febrile neutropenia (24 [9%] of 258 patients in the ramu

174 ll 285 serious adverse events recorded, were febrile neutropenia (27 [17%] of 155 serious adverse eve

175 utropenia (46%), thrombocytopenia (38%), and febrile neutropenia (29%).

176 adverse events (>=10% in either group) were febrile neutropenia (31 [42%] vs 28 [39%]), decreased wh

177 grade 3/4 toxicities were neutropenia (62%), febrile neutropenia (35%), and peripheral sensory neurop

178 ing infection (16.9% v 10.7%, respectively), febrile neutropenia (35.0% v 17.7%, respectively), mucos

179 onhematologic toxicities with regimen M were febrile neutropenia (39.2%) and infections (21.6%).

180 events, including incidence and severity of febrile neutropenia (41 [18%] patients in the A+CHP grou

181 ommon grade 3 or greater adverse events were febrile neutropenia (42%), thrombocytopenia (38%), and W

182 neutropenia (124 [60%] of 207 patients) and febrile neutropenia (48 [23%]), whereas in the placebo g

183 hematologic toxicities during induction were febrile neutropenia (55%) and sepsis (35%).

184 group), neutropenia (47 [15%] vs 92 [30%]), febrile neutropenia (57 [18%] vs 34 [11%]), leucopenia (

185 e 3/4 neutropenia (45.8% v 21.5%; P < .001), febrile neutropenia (6.3% v 3.7%; P = .019), and diarrhe

186 s irrespective of relation to treatment were febrile neutropenia (97 [39%] of 252), anaemia (61 [24%]

187 nts occurring in 5% or more of patients were febrile neutropenia (98 [39%] of 252; five related to tr

188 ), pneumonia (five [5%] and five [11%]), and febrile neutropenia (five [5%] and six [13%]).

189 ea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock

190 r more patients) were pneumonia (five [6%]), febrile neutropenia (five [6%]), pulmonary embolism (thr

191 nt (IEAT) in oncohematological patients with febrile neutropenia (FN) and its impact on mortality.

192 y group compared with pneumonia (four [4%]), febrile neutropenia (four [4%]), anaemia (three [3%]), a

193 vs 28 [6%]; grade 4, 98 [20%] vs 77 [15%]), febrile neutropenia (grade 3, 52 [10%] vs 31 [6%]; grade

194 th grades 3 or 4 neutropenia (n=79, 47%) and febrile neutropenia (n=49, 29%).

195 naemia (11 [25%]), leukopenia (seven [16%]), febrile neutropenia (seven [16%]), and pneumonia (seven

196 openia (eight [16%]), anaemia (seven [14%]), febrile neutropenia (six [12%]), and leucopenia (six [12

197 patients), thrombocytopenia (14 [17%]), and febrile neutropenia (ten [12%]).

198 vents were increased lipase (three [7%]) and febrile neutropenia (three [7%]).

199 neutropenia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group.

200 up (P = 0.07); events were related mainly to febrile neutropenia and infection.

201 Febrile neutropenia and sensory neuropathy incidences we

202 Prophylaxis prevented febrile neutropenia and systemic infection.

203 One patient experienced febrile neutropenia but was able to complete paclitaxel

204 An antibiotic cycling-based strategy for febrile neutropenia effectively reduced carbapenem use,

205 and the incidence of grade 4 neutropenia and febrile neutropenia favored pazopanib.

206 ed after paclitaxel only if patients had had febrile neutropenia in a prior cycle or at investigator

207 pulmonary fibrosis in group B and one due to febrile neutropenia in group C.

208 he most common grade 3-4 adverse events were febrile neutropenia in seven (14%) patients, decreased n

209 Febrile neutropenia occurred in 16% of cycles, and tumor

210 ignancy unit: monthly antibiotic cycling for febrile neutropenia that included cefepime (+/- metronid

211 Treatment-related febrile neutropenia was reported in 10% of patients.

212 Neutropenia and febrile neutropenia were key secondary end points.

213 11 (10%) patients, of which neutropenia and febrile neutropenia were the most common (five [5%] pati

214 11%] events), and anaemia and neutropenia or febrile neutropenia were the most frequent grade 3 or wo

215 event in the subcutaneous daratumumab group (febrile neutropenia) and four in the intravenous group (

216 A single serious adverse event (ie, grade 4 febrile neutropenia) was reported.

217 f 270 patients; nine [3%] vs no patients had febrile neutropenia), infections (86 [31%] vs 48 [18%]),

218 duced frequency and severity of neutropenia, febrile neutropenia, and infections.

219 imumab plus platinum-etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each];

220 0%) included nausea, diarrhea, constipation, febrile neutropenia, fatigue, hypokalemia, decreased app

221 Three serious adverse events-febrile neutropenia, intestinal perforation, and cholang

222 vents included one (3%) patient with grade 3 febrile neutropenia, one (3%) patient with grade 4 hyper

223 emia and neutropenia; 10 patients (9.3%) had febrile neutropenia.

224 most common noninfectious reactions include febrile nonhemolytic transfusion reactions, allergic tra

225 In 937 febrile, nonsevere neutropenia episodes, frequencies of

226 safely reduces unnecessary antibiotic use in febrile, nonseverely neutropenic pediatric patients with

227 s (>30 min); or with clusters of two or more febrile or afebrile seizures within a 24-h period were a

228 urrent prolonged (>10 min) febrile seizures; febrile or afebrile status epilepticus (>30 min); or wit

229 The association between the number of febrile outpatients and the proportion prescribed blood

230 Samples from 797 afebrile and 457 febrile outpatients from two provinces in Angola with kn

231 UMT sensitivity among febrile patients (for whom the test was indicated) was 8

232 n southeast Asia, antibiotic prescription in febrile patients attending primary care is common, and a

233 In febrile patients attending primary care, testing for CRP

234 and identify risk factors for brucellosis in febrile patients from a pastoralist community of Tanzani

235 re defined by positive RDT and controls were febrile patients from the same clinic with a negative RD

236 In this case-control study, we enrolled febrile patients presenting to outpatient departments at

237 we searched for methanogens in the blood of febrile patients using specific tools.

238 Surveillance for arboviral diseases among febrile patients was performed at an emergency health un

239 ted as causing archaemia and endocarditis in febrile patients who are coinfected by bacteria.

240 Malaria case counts among febrile patients within IRS areas was lower post- compar

241 In febrile patients, only a small proportion of infections

242 antigens did not differ between afebrile and febrile patients.

243 aria cases or sub-optimal case management of febrile patients.

244 We report a series of febrile pediatric patients with acute heart failure pote

245 Data were prospectively collected on febrile pediatric patients with cancer with a central ve

246 Management of febrile pediatric patients with cancer with an absolute

247 had been cultivated in MHB experienced short febrile periods (median, 3.2 days), limited weight loss

248 ad been cultivated in BHI experienced longer febrile periods (median, 5.5 days) and greater weight lo

249 for determination of malarial etiology among febrile persons.

250 e time-points, apparent already in the early febrile phase (1.29 vs 1.75; P = .012).

251 Febrile-range hyperthermia worsens and hypothermia mitig

252 ere judged to be related to vaccination (one febrile reaction and one anaphylaxis) and one possibly r

253 -triggered anaphylaxis, acute cardiovascular/febrile reactions).

254 inate between anaphylaxis and cardiovascular/febrile reactions, ROC curve analysis revealed a reasona

255 ic prior viral infections against subsequent febrile respiratory illness (FRI).

256 We conclude that the febrile response is dependent on local release of PGE2 o

257 These data imply that the febrile response is dependent on the local release of PG

258 Mammary treatment with LPS resulted in febrile response that was detectable in TN goats, but wa

259 hermoregulatory neurons, is critical for the febrile response to peripheral inflammation.

260 PGE2 level in the brain do not influence the febrile response.

261 ines and attenuated systemic circulatory and febrile responses, likely reflecting decreased systemic

262 ing for epilepsy type, sex, site, history of febrile seizure, and age at last observation.

263 tinct acute encephalopathy syndromes, simple febrile seizures (14), other seizures (16), acute ataxia

264 pilepsy was lower in patients with prolonged febrile seizures (14.3%, 6.3-29.4) and survivors of acut

265 ts from an epilepsy GWAS meta-analysis and a febrile seizures (FS) GWAS are significantly more enrich

266 a subset of children experiencing prolonged febrile seizures (FSs), the most common type of childhoo

267 was raised in individuals with a history of febrile seizures (hazard ratio [HR] 1.12, 95% CI 1.08-1.

268 tinct acute encephalopathy syndromes, simple febrile seizures (n = 14), other seizures (n = 16), acut

269 ased with a growing number of admissions for febrile seizures (p<0.0001) and with later onset of chil

270 were categorised according to occurrence of febrile seizures and epilepsy, before entering the follo

271 g of KCC2, found previously in patients with febrile seizures and epilepsy, has been demonstrated to

272 articipant (2.9%, 0.5-14.5) in the prolonged febrile seizures group developed temporal lobe epilepsy

273 Febrile seizures occurred after dose 1 of MMR vaccine at

274 included associations of SCN1A with "complex febrile seizures" (HP: 0011172; p = 2.1 x 10(-5)) and "f

275 43 148 individuals had a history of febrile seizures, 10 355 had epilepsy, and 1696 had both

276 ayed speech, a history of febrile and/or non-febrile seizures, and a wide-based, spastic, and/or stif

277 ry clinical discharge diagnoses (eg, sepsis, febrile seizures, dehydration, or other non-respiratory

278 drawal, age at onset of epilepsy, history of febrile seizures, number of seizures before remission, a

279 Children with epilepsy and febrile seizures-with and without concomitant epilepsy-a

280 itive problems in individuals suffering long febrile seizures.

281 resenting with recurrent prolonged (>10 min) febrile seizures; febrile or afebrile status epilepticus

282 nce of megalencephaly and ventriculomegaly, (febrile) seizures and autism-like behaviour.

283 n patient from New Caledonia presenting with febrile splenomegaly,weight loss, life-threatening autoi

284 o three months apart and are under long-term febrile surveillance to detect dengue by serotype-specif

285 b) Mass Screen and Treat (MSAT) classifed by febrile, symptomatic infections, and (c) Mass Test and T

286 opheles mosquitoes and presents with generic febrile symptoms that are challenging to diagnose clinic

287 with arthritogenic alphaviruses results in a febrile syndrome characterized by debilitating musculosk

288 d culture-confirmed enteric fever from other febrile syndromes.

289 The febrile Th2 switch was IL4 independent, but a gamma-secr

290 Vs) since TRPV1/TRPV4 antagonism blocked the febrile Th2 switch, while TRPV1 agonists mediated a Th2

291 patient recuperation starting from the early febrile to the defervescence and convalescent stages of

292 Dividing UTIs into three categories; febrile upper UTI (acute pyelonephritis), lower UTI (cys

293 A single episode of febrile UTI is often caused by a virulent Escherichia co

294 ations of atypical and recurrent episodes of febrile UTI should focus on urinary tract abnormalities,

295 No febrile UTI were recorded in the WOCA group vs. 9 (45.0%

296 No febrile UTIs were recorded in the WOCA group versus 9 (4

297 Secondary outcomes: number of febrile UTIs, number of hospitalisations, WOCA tolerance

298 Secondary outcomes were number of febrile UTIs, number of hospitalizations, WOCA tolerance

299 Forest disease (KFD) is a tick-borne, acute, febrile viral illness endemic in southern India.

300 reatment after a neutropenic patient becomes febrile, whether and how to modify the initial treatment